

=> d his nofile

(FILE 'HOME' ENTERED AT 13:32:22 ON 19 JUL 2006)

FILE 'CAPLUS' ENTERED AT 13:32:29 ON 19 JUL 2006

E US2003-716846/APPS

L1 2 SEA ABB=ON PLU=ON (US2003-716846/AP OR US2003-716846/PRN)
SEL RN L1

FILE 'REGISTRY' ENTERED AT 13:33:06 ON 19 JUL 2006

L2 76 SEA ABB=ON PLU=ON (91-56-5/BI OR 100-46-9/BI OR 103-71-9/BI
OR 106-95-6/BI OR 107-10-8/BI OR 1142-20-7/BI OR 115328-81-9/BI
OR 1161-13-3/BI OR 1164-16-5/BI OR 1195-45-5/BI OR 129833-54-1
/BI OR 16588-69-5/BI OR 2018-61-3/BI OR 20780-76-1/BI OR
220509-86-4/BI OR 2448-45-5/BI OR 2577-48-2/BI OR 29713-97-1/BI
OR 40397-98-6/BI OR 438576-16-0/BI OR 443-69-6/BI OR 4668-42-2
/BI OR 50528-86-4/BI OR 5241-58-7/BI OR 55289-36-6/BI OR
5672-83-3/BI OR 611-09-6/BI OR 627-37-2/BI OR 74213-24-4/BI OR
7432-21-5/BI OR 744198-09-2/BI OR 744198-10-5/BI OR 744198-11-6
/BI OR 744198-12-7/BI OR 744198-13-8/BI OR 744198-14-9/BI OR
744198-15-0/BI OR 744198-16-1/BI OR 744198-17-2/BI OR 744198-18
-3/BI OR 744198-19-4/BI OR 744198-20-7/BI OR 744198-21-8/BI OR
744198-22-9/BI OR 744198-23-0/BI OR 744198-24-1/BI OR 744198-25
-2/BI OR 744198-26-3/BI OR 744198-27-4/BI OR 744198-28-5/BI OR
744198-29-6/BI OR 80146-85-6/BI OR 80789-74-8/BI OR 98-80-6/BI
OR 109497-00-9/BI OR 132898-96-5/BI OR 242792-95-6/BI OR
504-73-4/BI OR 515-83-3/BI OR 642073-83-4/BI OR 64286-85-7/BI
OR 878552-29-5/BI OR 878552-30-8/BI OR 878552-31-9/BI OR
878663-49-1/BI OR 878663-54-8/BI OR 878663-58-2/BI OR 878663-59
-3/BI OR 878663-61-7/BI OR 878663-62-8/BI OR 878663-63-9/BI OR
878663-64-0/BI OR 878663-65-1/BI OR 878663-67-3/BI OR 878663-68
-4/BI OR 878663-75-3/BI)

L3 34 SEA ABB=ON PLU=ON L2 AND BR>0

L4 30 SEA ABB=ON PLU=ON L3 AND NOC3/ES

L5 6 SEA ABB=ON PLU=ON L4 AND NR=3

L6 2 SEA ABB=ON PLU=ON L5 AND C21 H22 BR N3 O4/MF
D L6 1-2

FILE 'REGISTRY' ENTERED AT 13:36:36 ON 19 JUL 2006

L7 STR 744198-15-0

L8 0 SEA FAM SAM L7
D L7

FILE 'REGISTRY' ENTERED AT 13:37:16 ON 19 JUL 2006

L9 STR 744198-09-2

L10 6 SEA FAM FUL L9

FILE 'CAPLUS' ENTERED AT 13:37:30 ON 19 JUL 2006

FILE 'REGISTRY' ENTERED AT 13:37:33 ON 19 JUL 2006

D SCAN L10

FILE 'CAPLUS' ENTERED AT 13:38:17 ON 19 JUL 2006

L11 7 SEA ABB=ON PLU=ON L10

FILE 'REGISTRY' ENTERED AT 13:38:51 ON 19 JUL 2006

L12 ANALYZE PLU=ON L10 1-6 LC : 4 TERMS
D

FILE 'BEILSTEIN' ENTERED AT 13:42:00 ON 19 JUL 2006

L13 2 SEA SSS FUL L9
L14 2 SEA ABB=ON PLU=ON L13 NOT L5
L15 0 SEA ABB=ON PLU=ON L14 AND BABSAN/FA

FILE 'MARPAT' ENTERED AT 13:44:02 ON 19 JUL 2006

L16 0 SEA SSS SAM L9
L17 1 SEA SSS FUL L9
L18 0 SEA ABB=ON PLU=ON L17 NOT L11

FILE 'CAPLUS' ENTERED AT 13:45:18 ON 19 JUL 2006

E KHOSLA C/AU
L19 270 SEA ABB=ON PLU=ON ("KHOSLA C"/AU OR "KHOSLA CHAITAN"/AU OR
"KHOSLA CHAITAN A"/AU OR "KHOSLA CHAITAN S"/AU OR "KHOSLA
CHAITAN SHIVKUMAR"/AU OR "KHOSLA CHAITIN"/AU OR "KHOSLA
CHAITON"/AU)
E CHOI K/AU
L20 4095 SEA ABB=ON PLU=ON CHOI K?/AU
L21 5 SEA ABB=ON PLU=ON L19 AND L20

FILE 'HCAPLUS' ENTERED AT 13:47:09 ON 19 JUL 2006

E CELIAC SPRUE/CT
E E3+ALL
L22 2522 SEA ABB=ON PLU=ON "CELIAC DISEASE"+PFT/CT
E DERMATITIS HERPETIFORMIS/CT
E E3+ALL
L23 207 SEA ABB=ON PLU=ON "DERMATITIS (L) HERPETIFORMIS"+PFT/CT
L24 373 SEA ABB=ON PLU=ON (CELIAC SPRUE? OR DERMATITIS HERPET?)/OBI,B
I
L25 2 SEA ABB=ON PLU=ON L11 AND (L22 OR L23 OR L24)
L26 7 SEA ABB=ON PLU=ON (L11 OR L25)
L27 7 SEA ABB=ON PLU=ON (L1 OR L26)

=> file caplus

FILE 'CAPLUS' ENTERED AT 13:49:41 ON 19 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jul 2006 VOL 145 ISS 4

FILE LAST UPDATED: 18 Jul 2006 (20060718/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que 121

L19 270 SEA FILE=CAPLUS ABB=ON PLU=ON ("KHOSLA C"/AU OR "KHOSLA CHAITAN"/AU OR "KHOSLA CHAITAN A"/AU OR "KHOSLA CHAITAN S"/AU OR "KHOSLA CHAITAN SHIVKUMAR"/AU OR "KHOSLA CHAITIN"/AU OR "KHOSLA CHAITON"/AU)
 L20 4095 SEA FILE=CAPLUS ABB=ON PLU=ON CHOI K?/AU
 L21 5 SEA FILE=CAPLUS ABB=ON PLU=ON L19 AND L20

=> d ibib abs 121 tot

L21 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:362104 CAPLUS
 DOCUMENT NUMBER: 144:404112
 TITLE: Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation
 AUTHOR(S): Strnad, Pavel; Siegel, Matthew; Toivola, Diana M.; Choi, Kihang; Kosek, Jon C.; Khosla, Chaitan; Omary, M. Bishr
 CORPORATE SOURCE: Department of Medicine, Palo Alto VA Medical Center, Palo Alto, CA, 94304, USA
 SOURCE: FEBS Letters (2006), 580(9), 2351-2357
 CODEN: FEBLAL; ISSN: 0014-5793
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Mallory bodies (MBs) are characteristic of several liver disorders, and consist primarily of keratins with transglutaminase-generated keratin crosslinks. We tested the effect of the transglutaminase-2 (TG2) inhibitor KCC009 on MB formation in a mouse model fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). KCC009 decreased DDC-induced liver enlargement without affecting MB formation or extent of liver injury. TG2 protein and activity increased after DDC feeding and localized within and outside hepatocytes. KCC009 inhibited DDC-induced hepatomegaly by affecting hepatocyte cell size rather than proliferation. Hence, TG2 is a potential mediator of injury-induced hepatomegaly via modulation of hepatocyte hypertrophy, and KCC009-mediated TG2 inhibition does not affect mouse MB formation.


REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:217140 CAPLUS
 DOCUMENT NUMBER: 144:293068
 TITLE: Preparation of dihydroisoxazole and isatin derivatives for use in pharmaceutical compositions as transglutaminase inhibitors
 INVENTOR(S): Khosla, Chaitan; Watts, Richard Edward; Siegel, Matthew John; Pinkas, Daniel M.; Choi, Kihang; Rich, Keith M.
 PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior University, USA
 SOURCE: U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S. Ser. No. 716,846.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006052308	A1	20060309	US 2005-213173	20050826
US 2004167069	A1	20040826	US 2003-716846	20031118
PRIORITY APPLN. INFO.:			US 2003-716846	A2 20031118
			US 2002-380761P	P 20020514 → <i>Entered</i> APD
			US 2002-392782P	P 20020628
			US 2002-422933P	P 20021031
			US 2002-428033P	P 20021120
			WO 2003-US15343	A2 20030514

OTHER SOURCE(S): MARPAT 144:293068
GI



AB Transglutaminase (tTGase) inhibitors, such as I [R₁, R₂ = H, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkoxy, alkylthio, halogen, etc.; R₃ = Cl, Br; X = NH, O; X₁ = (CH₂)_n, n = 0-10] and II [R₄ = alkylamino, benzylamino, amino acid residue, etc.], were prepared for therapeutic use in the treatment of neurol. cancers. Thus, dihydroisoxazole phenylalanine derivative III was prepared with 52% yield by an amidation reaction of 3-bromo-5-aminomethyl-4,5-dihydroisoxazole with N-(benzyloxycarbonyl)-L-phenylalanine using HOBt in DMF. The prepared dihydroisoxazoles, isatins and peptides were tested for tTGase-2 inhibitory activity and for inhibition of astrocytoma, glioblastoma, and meningioma tumors.

L21 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1064565 CAPLUS

DOCUMENT NUMBER: 144:246627

TITLE: Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas

AUTHOR(S): Yuan, Liya; Choi, Kihang; Khosla, Chaitan; Zheng, Xiao; Higashikubo, Ryuji; Chicoine, Michael R.; Rich, Keith M.

CORPORATE SOURCE: Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA

SOURCE: Molecular Cancer Therapeutics (2005), 4(9), 1293-1302

CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Tissue transglutaminase 2 belongs to a family of transglutaminase proteins that confers mech. resistance from proteolysis and stabilizes proteins. Transglutaminase 2 promotes transamidation between glutamine and lysine residues with the formation of covalent linkages between proteins. Transglutaminase 2 also interacts and forms complexes with proteins important in extracellular matrix organization and cellular adhesion. We have identified the novel finding that treatment of glioblastoma cells with transglutaminase 2 inhibitors promotes cell death and enhances sensitivity to chemotherapy. Treatment with either the competitive transglutaminase 2 inhibitor, monodansylcadaverine, or with highly specific small-mol. transglutaminase 2 inhibitors, KCA075 or KCC009, results in induction of apoptosis in glioblastoma cells. Treatment with these transglutaminase 2 inhibitors resulted in markedly decreased levels of the prosurvival protein, phosphorylated Akt, and its downstream targets. These changes promote a proapoptotic profile with altered levels of multiple intracellular proteins that determine cell survival. These changes include decreased levels of the antiapoptotic proteins, survivin, phosphorylated Bad, and phosphorylated glycogen synthetase kinase 3 β (GSK-3 β), and increased levels of the proapoptotic BH3-only protein, Bim. In vivo studies with s.c. murine DBT glioblastoma tumors treated with transglutaminase 2 inhibitors combined with the chemotherapeutic agent, N-N'-bis (2-chloroethyl)-N-nitrosourea (BCNU), decreased tumor size based on weight by 50% compared with those treated with BCNU alone. Groups treated with transglutaminase 2 inhibitors showed an increased incidence of apoptosis determined with deoxynucleotidyl transferase-mediated biotin nick-end labeling staining. These studies identify inhibition of transglutaminase 2 as a potential target to enhance cell death and chemosensitivity in glioblastomas.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:356173 CAPLUS

DOCUMENT NUMBER: 143:125809

TITLE: Chemistry and Biology of Dihydroisoxazole Derivatives: Selective Inhibitors of Human Transglutaminase 2

AUTHOR(S): Choi, Kihang; Siegel, Matthew; Piper, Justin L.; Yuan, Liya; Cho, Eun; Strnad, Pavel; Omary, Bishr; Rich, Keith M.; Khosla, Chaitan

CORPORATE SOURCE: Department of Chemistry, Stanford University, Stanford, CA, 94305, USA

SOURCE: Chemistry & Biology (2005), 12(4), 469-475

CODEN: CBOLE2; ISSN: 1074-5521

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Summary: 3-Halo-4,5-dihydroisoxazoles are attractive warheads for the selective inhibition of nucleophilic active sites in biol. systems. A series of 3-bromo-4,5-dihydroisoxazole compds. were prepared and tested for their ability to irreversibly inhibit human transglutaminase 2 (TG2), an enzyme that plays an important role in the pathogenesis of diverse disorders including Celiac Sprue and certain types of cancers. Several compds. showed high specificity for human TG2 ($k_{inh}/K_I > 2000 \text{ min}^{-1}\text{M}^{-1}$) but essentially no reactivity ($k < 1 \text{ min}^{-1}\text{M}^{-1}$) toward physiol. thiols such as glutathione. The pharmacokinetic and pharmacodynamic properties of a prototype dihydroisoxazole inhibitor, 1b, were evaluated; in mice the compound showed good oral bioavailability, short serum half-life and

efficient TG2 inhibition in small intestinal tissue, and low toxicity. It also showed excellent synergism with N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine) against refractory glioblastoma tumors in mice. A fluorescent dihydroisoxazole inhibitor 5 facilitated microscopic visualization of TG2 endocytosis from the extracellular surface of HCT-116 cells. Together, these findings demonstrate the promise of dihydroisoxazole compds. as probes for the biol. of TG2 and its role in human disease.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:703116 CAPLUS

DOCUMENT NUMBER: 141:218994

TITLE: Tissue transglutaminase (tTGase) inhibitor therapy for celiac sprue and dermatitis herpetiformis

INVENTOR(S): Khosla, Chaitan; Choi, Kihang

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of Appl. No. PCT/US03/15343.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167069	A1	20040826	US 2003-716846	20031118
CA 2487247	AA	20031127	CA 2003-2487247	20030514
WO 2003096979	A2	20031127	WO 2003-US15343	20030514
WO 2003096979	A3	20040212		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003096984	A2	20031127	WO 2003-US15506	20030514
WO 2003096984	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003234597	A1	20031202	AU 2003-234597	20030514
AU 2003234634	A1	20031202	AU 2003-234634	20030514
EP 1507549	A2	20050223	EP 2003-728939	20030514
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

CA 2502700 AA 20040603 CA 2003-2502700 20031120
 WO 2004045392 A2 20040603 WO 2003-US37434 20031120
 WO 2004045392 A3 20040826
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003294473 A1 20040615 AU 2003-294473 20031120
 EP 1563300 A2 20050817 EP 2003-789958 20031120
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 WO 2005049064 A1 20050602 WO 2004-US37873 20041112
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 US 2005256054 A1 20051117 US 2005-514005 20050513
 US 2006035838 A1 20060216 US 2005-514177 20050628
 US 2006052308 A1 20060309 US 2005-213173 20050826
 PRIORITY APPLN. INFO.: US 2002-380761P P 20020514 APP
 US 2002-392782P P 20020628
 US 2002-422933P P 20021031
 US 2002-428033P P 20021120
 WO 2003-US15343 A2 20030514
 WO 2003-US15506 W 20030514
 US 2003-716846 A 20031118
 WO 2003-US37434 W 20031120

OTHER SOURCE(S): MARPAT 141:218994

AB Administering an ED of a tTGase inhibitor to a celiac sprue or dermatitis
 herpetiformis patient reduces the toxic effects of toxic gluten
 oligopeptides, thereby attenuating or eliminating the damaging effects of
 gluten. Preparation and tissue transglutaminase-inhibiting activity of
 dihydroisoxazole moiety-containing compds. is included.

=> file hcaplus

FILE 'HCAPLUS' ENTERED AT 13:49:53 ON 19 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jul 2006 VOL 145 ISS 4
FILE LAST UPDATED: 18 Jul 2006 (20060718/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> d que 127

L1 2 SEA FILE=CAPLUS ABB=ON PLU=ON (US2003-716846/AP OR US2003-716
846/PRN)

L9 STR



Page 1-A



Page 2-A

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE

L10 6 SEA FILE=REGISTRY FAM FUL L9
 L11 7 SEA FILE=CAPLUS ABB=ON PLU=ON L10
 L22 2522 SEA FILE=HCAPLUS ABB=ON PLU=ON "CELIAC DISEASE"+PFT/CT
 L23 207 SEA FILE=HCAPLUS ABB=ON PLU=ON "DERMATITIS (L) HERPETIFORMIS"
 +PFT/CT
 L24 373 SEA FILE=HCAPLUS ABB=ON PLU=ON (CELIAC SPRUE? OR DERMATITIS
 HERPET?)/OBI, BI
 L25 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (L22 OR L23 OR L24)
 L26 7 SEA FILE=HCAPLUS ABB=ON PLU=ON (L11 OR L25)
 L27 7 SEA FILE=HCAPLUS ABB=ON PLU=ON (L1 OR L26)

=> d ibib abs hitstr l27 tot

L27 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:217140 HCAPLUS

DOCUMENT NUMBER: 144:293068

TITLE: Preparation of dihydroisoxazole and isatin derivatives
 for use in pharmaceutical compositions as
 transglutaminase inhibitors

INVENTOR(S): Khosla, Chaitan; Watts, Richard Edward; Siegel,
 Matthew John; Pinkas, Daniel M.; Choi, Kihang; Rich,
 Keith M.

PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior
 University, USA

SOURCE: U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S.
 Ser. No. 716,846.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006052308	A1	20060309	US 2005-213173	20050826 <--
US 2004167069	A1	20040826	US 2003-716846	20031118 <--
PRIORITY APPLN. INFO.:			US 2003-716846	A2 20031118 <--
			US 2002-380761P	P 20020514 APP.
			US 2002-392782P	P 20020628
			US 2002-422933P	P 20021031
			US 2002-428033P	P 20021120
			WO 2003-US15343	A2 20030514

OTHER SOURCE(S): MARPAT 144:293068

GI



AB Transglutaminase (tTGase) inhibitors, such as I [R1, R2 = H, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkoxy, alkylthio, halogen, etc.; R3 = Cl, Br; X = NH, O; X1 = (CH2)*n*, *n* = 0-10] and II [R4 = alkylamino, benzylamino, amino acid residue, etc.], were prepared for therapeutic use in the treatment of neurol. cancers. Thus, dihydroisoxazole phenylalanine derivative III was prepared with 52% yield by an amidation reaction of 3-bromo-5-aminomethyl-4,5-dihydroisoxazole with N-(benzyloxycarbonyl)-L-phenylalanine using HOBt in DMF. The prepared dihydroisoxazoles, isatins and peptides were tested for tTGase-2 inhibitory activity and for inhibition of astrocytoma, glioblastoma, and meningioma tumors.

IT 744198-09-2P 744198-15-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydroisoxazole and isatin derivs. for use in pharmaceutical compns. as transglutaminase-2 inhibitors)

RN 744198-09-2 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 744198-15-0 HCAPLUS

CN Carbamic acid, [(1R)-2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:356173 HCAPLUS

DOCUMENT NUMBER: 143:125809

TITLE: Chemistry and Biology of Dihydroisoxazole Derivatives: Selective Inhibitors of Human Transglutaminase 2

AUTHOR(S): Choi, Kihang; Siegel, Matthew; Piper, Justin L.; Yuan, Liya; Cho, Eun; Strnad, Pavel; Omary, Bishr; Rich, Keith M.; Khosla, Chaitan

CORPORATE SOURCE: Department of Chemistry, Stanford University, Stanford, CA, 94305, USA

SOURCE: Chemistry & Biology (2005), 12(4), 469-475

CODEN: CBOLE2; ISSN: 1074-5521

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Summary: 3-Halo-4,5-dihydroisoxazoles are attractive warheads for the selective inhibition of nucleophilic active sites in biol. systems. A series of 3-bromo-4,5-dihydroisoxazole compds. were prepared and tested for their ability to irreversibly inhibit human transglutaminase 2 (TG2), an enzyme that plays an important role in the pathogenesis of diverse disorders including Celiac Sprue and certain types of cancers. Several compds. showed high specificity for human TG2 ($k_{inh}/K_I > 2000 \text{ min}^{-1}\text{M}^{-1}$) but essentially no reactivity ($k < 1 \text{ min}^{-1}\text{M}^{-1}$) toward physiol. thiols such as glutathione. The pharmacokinetic and pharmacodynamic properties of a prototype dihydroisoxazole inhibitor, 1b, were evaluated; in mice the compound showed good oral bioavailability, short serum half-life and efficient TG2 inhibition in small intestinal tissue, and low toxicity. It also showed excellent synergism with N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine) against refractory glioblastoma tumors in mice. A fluorescent dihydroisoxazole inhibitor 5 facilitated microscopic visualization of TG2 endocytosis from the extracellular surface of HCT-116 cells. Together, these findings demonstrate the promise of dihydroisoxazole compds. as probes for the biol. of TG2 and its role in human disease.

IT 744198-09-2 744198-15-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dihydroisoxazole derivs. as inhibitors of human transglutaminase)

RN 744198-09-2 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 744198-15-0 HCAPLUS

CN Carbamic acid, [(1R)-2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:703116 HCAPLUS

DOCUMENT NUMBER: 141:218994

TITLE: Tissue transglutaminase (tTGase) inhibitor therapy for celiac sprue and dermatitis herpetiformis

INVENTOR(S): Khosla, Chaitan; Choi, Kihang

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of Appl. No. PCT/US03/15343.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167069	A1	20040826	US 2003-716846	20031118 <--
CA 2487247	AA	20031127	CA 2003-2487247	20030514
WO 2003096979	A2	20031127	WO 2003-US15343	20030514
WO 2003096979	A3	20040212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2003096984 A2 20031127 WO 2003-US15506 20030514
 WO 2003096984 A3 20040701
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003234597 A1 20031202 AU 2003-234597 20030514
 AU 2003234634 A1 20031202 AU 2003-234634 20030514
 EP 1507549 A2 20050223 EP 2003-728939 20030514
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CA 2502700 AA 20040603 CA 2003-2502700 20031120
 WO 2004045392 A2 20040603 WO 2003-US37434 20031120
 WO 2004045392 A3 20040826
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003294473 A1 20040615 AU 2003-294473 20031120
 EP 1563300 A2 20050817 EP 2003-789958 20031120
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 WO 2005049064 A1 20050602 WO 2004-US37873 20041112 <--
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2005256054 A1 20051117 US 2005-514005 20050513
 US 2006035838 A1 20060216 US 2005-514177 20050628
 US 2006052308 A1 20060309 US 2005-213173 20050826 <--
 PRIORITY APPLN. INFO.: US 2002-380761P P 20020514 APP
 US 2002-392782P P 20020628
 US 2002-422933P P 20021031
 US 2002-428033P P 20021120
 WO 2003-US15343 A2 20030514
 WO 2003-US15506 W 20030514

US 2003-716846 A 20031118 <--
WO 2003-US37434 W 20031120

OTHER SOURCE(S): MARPAT 141:218994

AB Administering an ED of a tTGase inhibitor to a celiac sprue or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. Preparation and tissue transglutaminase-inhibiting activity of dihydroisoxazole moiety-containing compds. is included.

IT 744198-09-2P 744198-15-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tissue transglutaminase inhibitor therapy for celiac sprue and dermatitis herpetiformis)

RN 744198-09-2 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 744198-15-0 HCAPLUS

CN Carbamic acid, [(1R)-2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:444144 HCAPLUS

DOCUMENT NUMBER: 119:44144

TITLE: Solid-state carbon-13 NMR study of a transglutaminase-inhibitor adduct

AUTHOR(S): Auger, Michele; McDermott, Ann E.; Robinson, Valerie; Castelhana, Arlindo L.; Billedeau, Roland J.; Pliura, Diana H.; Krantz, Allen; Griffin, Robert G.

CORPORATE SOURCE: Francis Bitter Natl. Magnet Lab., Massachusetts Inst.

Technol., Cambridge, MA, 02139, USA
 SOURCE: Biochemistry (1993), 32(15), 3930-4
 CODEN: BICHAW; ISSN: 0006-2960
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Solid-state ^{13}C NMR was used to study the structure of the adduct resulting from the inactivation of transglutaminase by 3-halo-4,5-dihydroisoxazoles. These inhibitors were conceived on the assumption that they would inhibit transglutaminase by attack of an enzyme active site cysteine SH group on the imine C atom of the dihydroisoxazole ring. The tetrahedral intermediate formed could then break down with the loss of the halide group and the subsequent formation of a stable imino thioether adduct. The ^{13}C CPMAS NMR spectra of the chloro-, bromo-, and (ethylthio)dihydroisoxazole inhibitors were compared, and the results indicated that the chemical shift of the C-3 atom is sensitive to the nature of the heteroatom. Subtraction of the natural-abundance ^{13}C solid-state NMR spectrum of the enzyme from that of the enzyme inactivated by C-3-labeled chlorodihydroisoxazole revealed a broad peak at 156 ppm. The chemical shift of this peak was very close to that observed for a model 3-ethylthio compound and suggested the formation of a stable imino thioether enzyme adduct. Similar results were obtained for lyophilized enzyme adducts and for frozen solns. of the enzyme adduct in the absence and presence of Ca^{2+} . These results were compared with those obtained by solution NMR on an aqueous solution of the enzyme-inhibitor complex. The ^{13}C -labeled C-3 resonance was not observed in this case.


IT 148416-83-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 148416-83-5 HCAPLUS

CN Carbamic acid, [2-[[[3-bromo-4,5-dihydro-5-isoxazolyl-3- ^{13}C]methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 120244-83-9 120244-83-9D, transglutaminase adducts


RL: PRP (Properties)

(structure of, solid-state carbon-13 NMR study of)

RN 120244-83-9 HCAPLUS


CN Carbamic acid, [2-[[[3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 120244-83-9 HCAPLUS
 CN Carbamic acid, [2-[[[3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:557401 HCAPLUS
 DOCUMENT NUMBER: 117:157401
 TITLE: Transglutaminase inhibitors as hair growth inhibitors
 INVENTOR(S): Handelsman, Joseph H.; Shander, Douglas; Funkhouser, Margaret G.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 12 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

*Other
 New?*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9211007	A1	19920709	WO 1991-US9645	19911219
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
→ US 5143925	A	19920901	US 1991-794321	19911112
CA 2098102	AA	19920620	CA 1991-2098102	19911219
CA 2098102	C	19961105		
AU 9191653	A1	19920722	AU 1991-91653	19911219
AU 656550	B2	19950209		
EP 563301	A1	19931006	EP 1992-903695	19911219
EP 563301	B1	20000510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				

JP 06504057 T2 19940512 JP 1991-503400 19911219
 AT 192644 E 20000515 AT 1992-903695 19911219
 ES 2145005 T3 20000701 ES 1992-903695 19911219
 PRIORITY APPLN. INFO.: US 1990-632126 A1 19901220
 WO 1991-US9645 A 19911219


AB The rate and character of mammalian hair growth is altered by topical application to the skin of a composition containing an inhibitor of the transglutaminase. A topical composition contained 5-(N-benzyloxycarbonyl-L-phenylalaninamido-methyl)-3-bromo-4,5-dihydroisoxazole 20, acetone 75, propylene carbonate 20, benzyl alc. 5%. The application of above composition on hamster skin for 18 days inhibited the hair mass by 87.87%.

IT 115329-49-2

RL: BIOL (Biological study)
 (as hair growth inhibitor, topical composition containing)

RN 115329-49-2 HCAPLUS

CN Carbamic acid, [2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L27 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:193339 HCAPLUS

DOCUMENT NUMBER: 110:193339

TITLE: Synthesis, chemistry, and absolute configuration of novel transglutaminase inhibitors containing a 3-halo-4,5-dihydroisoxazole

AUTHOR(S): Castelhana, Arlindo L.; Billedeau, Roland; Pliura, Diana H.; Bonaventura, Bonnie J.; Krantz, Allen

CORPORATE SOURCE: Syntex Inc., Mississauga, ON, L5N 3X4, Can.

SOURCE: Bioorganic Chemistry (1988), 16(3), 335-40

CODEN: BOCMBM; ISSN: 0045-2068

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:193339

AB The preparation of potent transglutaminase inhibitors containing a 3-halo-4,5-dihydroisoxazole and the determination of their absolute configuration are

described. Interestingly, reaction of halodihydroisoxazoles with thiolate is dependent on the nature of the halogen atom, with the bromide primarily undergoing ring cleavage and the chloride undergoing displacement with the ring intact. This result may have implications as regards mechanisms of transglutaminase inhibition by 3-halo-4,5-dihydroisoxazoles.


IT 120244-83-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (inactivation by, of transglutaminase)

RN 120244-83-9 HCAPLUS


CN Carbamic acid, [2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 120245-03-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 120245-03-6 HCAPLUS
 CN Carbamic acid, [2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, [R-(R*,S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L27 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1989:76070 HCAPLUS
 DOCUMENT NUMBER: 110:76070
 TITLE: Preparation and testing of amino acid amides of 5-(aminomethyl)-4,5-dihydroisoxazoles as transglutaminase inhibitors
 INVENTOR(S): Castelhana, Arlindo L.; Krantz, Alexander; Pliura, Diana H.; Venuti, Michael C.; De Young, Lawrence M.
 PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
 SOURCE: Eur. Pat. Appl., 95 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 237082	A2	19870916	EP 1987-103700	19870313
EP 237082	A3	19880914		
EP 237082	B1	19910529		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8701303	A	19870915	DK 1987-1303	19870313
AU 8769987	A1	19870917	AU 1987-69987	19870313
AU 599636	B2	19900726		

JP 62252779	A2	19871104	JP 1987-59922	19870313
HU 44244	A2	19880229	HU 1987-1105	19870313
HU 201032	B	19900928		
ZA 8701860	A	19881026	ZA 1987-1860	19870313
US 4912120	A	19900327	US 1987-25451	19870313
IL 81887	A1	19910512	IL 1987-81887	19870313
IL 95264	A1	19910512	IL 1987-95264	19870313
AT 63906	E	19910615	AT 1987-103700	19870313
ES 2038609	T3	19930801	ES 1987-103700	19870313
US 4929630	A	19900529	US 1989-404791	19890908
PRIORITY APPLN. INFO.:			US 1986-839743	A 19860314
			EP 1987-103700	A 19870313
			IL 1987-81887	A 19870313
			US 1987-25451	A3 19870313

OTHER SOURCE(S): CASREACT 110:76070; MARPAT 110:76070
GI




AB The title compds. [I; R = R₁R₂NCHR₃CONHCH₂, R₂ = NHCH₂; NR₁R₂ = phthalimido; R₁R₃ = (CH₂)₃, CH₂CH(OH)CH₂; R₁ = H, Me; R₂ = H, alkyl, lower alkylsulfonyl, (lower alkyl)arylsulfonyl, 9-fluorenylmethyloxycarbonyl, succinyl, cinnamoyl, CHO, alkanoyl, amino acid residue, etc.; R₃ = H, lower alkyl, CHMeOCH₂Ph, CH₂CONH₂, (CH₂)₂NH₂, (CH₂)₄NHCO₂CMe₃, (CH₂)₂CH(OH)CH₂NH₂, (un)substituted phenylalkyl, etc.; X = halo, OR₄, SR₄, S(O)R₄, SO₂R₄, SO₂NH₂, SO₂NHR₄; R₄ = lower alkyl, fluorinated C₂-3 alkyl, (un)substituted aryl, (un)substituted NH₂, 1H-imidazol-1-yl] (II), useful as transglutaminase inhibitors, were prepared. To a solution of 700 mg N-benzyloxycarbonyl-L-phenylalanine allyl amide in EtOAc/H₂O was added NaHCO₃ and in small portions 631 mg dibromoformaldoxime. The progress of the reaction was monitored by thin layer chromatog. and after completion of the reaction (2-4 h) the mixture was worked up to give I (R = CBZ-Phe, X = Br) (IV). A gel consisting of IV, 2.5% Klurel, 10% diisopropyl adipate, 80% EtOH and 5% polyethylene glycol was applied once daily to two dogs for 14 days, resulting in clearing of majority of blackhead-like lesions as well as many whitehead-like lesions. A gel formulation containing 1 IV, 3 H₂O, 2 Carbopol, 0.01 Pr gallate, and 0.01% edetate disodium in 100 mL propylene glycol was given.

IT 115329-49-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as transglutaminase inhibitor)

RN 115329-49-2 HCAPLUS

CN Carbamic acid, [2-[[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



=> file beils

FILE 'BEILSTEIN' ENTERED AT 13:50:08 ON 19 JUL 2006

COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON JUNE 16, 2006

FILE COVERS 1771 TO 2006.

*** FILE CONTAINS 9,606,495 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.
Reaction data for BEILSTEIN compounds may be displayed
immediately with the display codes PRE (preparations) and REA
(reactions). A substance answer set retrieved after the search
for a chemical name, a compounds with available reaction
information by combining with PRE/FA, REA/FA or more generally
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
between a BEILSTEIN compound and belonging reactions. For mo
detailed reaction searches BRNs can be searched as reaction
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<


* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

NEW


* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE
SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,
ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A
COMPOUND AT A GLANCE.

=> d que 113

L9 STR



Page 1-A



Page 2-A

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
L13 2 SEA FILE=BEILSTEIN SSS FUL L9


=> d ide allref l13 tot

L13 ANSWER 1 OF 2 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5386200
CAS Reg. No. (RN):	115329-50-5, 120244-89-5, 120244-90-8
Chemical Name (CN):	<1-(3-bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl>-2-(4-hydroxy-phenyl)-

→
Same as 2/2

Autonom Name (AUN): ethyl>-carbamic acid benzyl ester
 <1-<(3-bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl>-2-(4-hydroxy-phenyl)-ethyl>-carbamic acid benzyl ester
 Molec. Formula (MF): C21 H22 Br N3 O5
 Molecular Weight (MW): 476.33
 Lawson Number (LN): 31551, 16193, 5228, 1762
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): heterocyclic
 Constitution ID (CONSID): 4730068
 Tautomer ID (TAUTID): 5126818
 Beilstein Citation (BSO): 6-27
 Entry Date (DED): 1993/05/04
 Update Date (DUPD): 1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
RN	CAS Registry Number	3
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:


Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Rohloff, John C.; Robinson, James III; Gardner, John O., Tetrahedron Lett., CODEN: TELEAY, 33(22), <1992>, 3113-3116; BABS-5654059

L13 ANSWER. 2 OF 2 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5386199
 CAS Reg. No. (RN): 115329-50-5, 120244-89-5, 120244-90-8
 Chemical Name (CN): <1-<(3-bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl>-2-(4-hydroxy-phenyl)-ethyl>-carbamic acid benzyl ester
 Autonom Name (AUN): <1-<(3-bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl>-2-(4-hydroxy-phenyl)-ethyl>-carbamic acid benzyl ester
 Molec. Formula (MF): C21 H22 Br N3 O5
 Molecular Weight (MW): 476.33
 Lawson Number (LN): 31551, 16193, 5228, 1762
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): heterocyclic
 Constitution ID (CONSID): 4730068
 Tautomer ID (TAUTID): 5126818
 Beilstein Citation (BSO): 6-27
 Entry Date (DED): 1993/05/04
 Update Date (DUPD): 1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
RN	CAS Registry Number	3
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1

FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

All References:

ALLREF

1. Rohloff, John C.; Robinson, James III; Gardner, John O., Tetrahedron Lett., CODEN: TELEAY, 33(22), <1992>, 3113-3116; BABS-5654059